List of Tables
    Table 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Opportunities & Trends in Global Market
    Table 2. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers in Global Market
    Table 3. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints in Global Market
    Table 4. Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist in Global Market
    Table 5. Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Type
    Table 9. List of Global Tier 1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2023-2028
    Table 30. Pfizer Corporate Summary
    Table 31. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 32. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 33. Novartis Corporate Summary
    Table 34. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 35. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 36. Merck Corporate Summary
    Table 37. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 38. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 39. AstraZeneca Corporate Summary
    Table 40. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 41. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 42. Jhonson and Johnson Corporate Summary
    Table 43. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 44. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 45. Eli Lilly Corporate Summary
    Table 46. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 47. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 48. Sanofi Corporate Summary
    Table 49. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 50. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 51. Bristol-Myers Squibb Corporate Summary
    Table 52. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 53. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 54. Bayer Corporate Summary
    Table 55. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 56. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 57. GSK Corporate Summary
    Table 58. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 59. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 60. Teva Pharmaceutical Corporate Summary
    Table 61. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 62. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 63. Shenzhen Salubris Pharmaceuticals  Corporate Summary
    Table 64. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 65. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 66. Sun Pharmaceutical Corporate Summary
    Table 67. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 68. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 69. Mylan Corporate Summary
    Table 70. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 71. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 72. Alembic Pharmaceuticals Corporate Summary
    Table 73. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 74. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 75. Lupin Corporate Summary
    Table 76. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 77. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 78. Aurobindo Pharma Corporate Summary
    Table 79. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 80. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 81. Amneal Pharmaceuticals Corporate Summary
    Table 82. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 83. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
    Table 84. Boehringer Ingelheim Corporate Summary
    Table 85. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Offerings
    Table 86. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Segment by Type in 2021
    Figure 2. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Segment by Application in 2021
    Figure 3. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2021
    Figure 8. By Type - Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 12. US Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 16. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 17. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 24. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 28. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 30. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share, 2017-2028
    Figure 33. Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (US$, Mn), 2017-2028
    Figure 37. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 47. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 48. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 49. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 50. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 51. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 52. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 53. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 54. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 55. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)